| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752199 | MALLINCKRODT ARD | Methods of modulating pericytes |
Feb, 2041
(16 years from now) | |
Acthar Gel is owned by Mallinckrodt Ard.
Acthar Gel contains Corticotropin.
Acthar Gel has a total of 1 drug patent out of which 0 drug patents have expired.
Acthar Gel is available in injectable;injection dosage forms.
Acthar Gel can be used as treatment of ophthalmic diseases with corticotropin by promoting new vessel formation wherein vcam-1 expression and angiopoetin-2 expression is increased after the administering.
The generics of Acthar Gel are possible to be released after 25 February, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 15, 2017 |
Drugs and Companies using CORTICOTROPIN ingredient
Treatment: Treatment of ophthalmic diseases with corticotropin by promoting new vessel formation wherein vcam-1 expression and angiopoetin-2 expression is increased after the administering
Dosage: INJECTABLE;INJECTION
ACTHAR GEL family patents
